Morepen Laboratories Limited

Informe acción NSEI:MOREPENLAB

Capitalización de mercado: ₹42.7b

Morepen Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Morepen Laboratories ha aumentado sus beneficios a una tasa media anual de 11.3%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 13.4% anual. Los ingresos han ido creciendo a una tasa media de 13.6% al año. La rentabilidad financiera de Morepen Laboratories es de 11.9%, y sus márgenes netos son de 7.4%.

Información clave

11.3%

Tasa de crecimiento de los beneficios

7.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 17.5%
Tasa de crecimiento de los ingresos13.6%
Rentabilidad financiera11.9%
Margen neto7.4%
Última actualización de beneficios30 Sep 2024

Actualizaciones de resultados anteriores recientes

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Aug 09
Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Recent updates

There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump

Aug 20
There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump

Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Aug 09
Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)

Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified

Jul 05
Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified

Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?

Jun 13
Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?

Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Apr 23
Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing

Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Nov 23
Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 22
Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Aug 10
Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Sep 21
Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Apr 05
Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?

Sep 14
Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?

Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

May 21
Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?

Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?

Mar 12
Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?

Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay

Feb 22
Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay

Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 07
Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain

Jan 21
Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain

Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet

Jan 03
Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet

Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?

Dec 16
Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?

Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Nov 28
Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?

Desglose de ingresos y gastos

Cómo gana y gasta dinero Morepen Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NSEI:MOREPENLAB Ingresos, gastos y beneficios (INR Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 2417,7481,3132,0170
30 Jun 2417,5711,1771,9980
31 Mar 2417,0199621,9350
31 Dec 2316,4227612,1270
30 Sep 2315,4335311,9580
30 Jun 2315,2384772,8840
31 Mar 2314,2203871,6540
31 Dec 2214,2704281,8000
30 Sep 2214,7655531,8430
30 Jun 2214,7217682,6040
31 Mar 2215,5581,0171,7240
31 Dec 2114,7431,1611,8090
30 Sep 2113,8541,1841,5890
30 Jun 2113,2951,0822,0920
31 Mar 2111,9809711,4070
31 Dec 2011,1368141,3450
30 Sep 2010,3806841,2790
30 Jun 209,1834531,6780
31 Mar 208,5843361,1430
31 Dec 198,7313311,1610
30 Sep 198,5303121,1180
30 Jun 198,1173401,4740
31 Mar 197,7142889950
31 Dec 187,2582529800
30 Sep 186,6722678790
30 Jun 186,4363088410
31 Mar 186,1012968070
31 Mar 175,9912367390
31 Mar 164,8611286160
31 Mar 154,014215170
31 Mar 143,670-288074

Ingresos de calidad: MOREPENLAB tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: Los actuales márgenes de beneficio (7.4%) de MOREPENLAB son superiores a los del año pasado (3.4%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de MOREPENLAB han crecido un 11.3% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de MOREPENLAB en el último año (147.1%) supera su media de 5 años (11.3% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de MOREPENLAB en el último año (147.1%) superó al de la industria Pharmaceuticals 20%.


Rentabilidad financiera

Alta ROE: La rentabilidad financiera de MOREPENLAB (11.9%) se considera baja.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado